Testing JSKN016 for advanced non-small cell lung cancer
Part of Cancer clinical trials.
This trial tests a new drug called JSKN016 for people with advanced non-small cell lung cancer (NSCLC) that has not responded to standard treatments. It may help those with certain gene changes or after prior therapy has failed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have advanced non-small cell lung cancer that cannot be removed by surgery or treated with radiation alone.
- Your cancer must have either a specific EGFR gene change and not responded to EGFR-targeted therapy, or no known driver gene and failed immunotherapy plus chemo, or have another driver gene and failed standard treatment.
- You must have at least one measurable tumor outside the brain.
- You must be able to provide a recent or fresh tumor tissue sample.
- You must not have had prior treatment with certain drugs including topoisomerase I inhibitors, docetaxel, or antibody-drug conjugates targeting TROP2 or HER3.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug combination for people with advanced non-small cell lung cancer (NSCLC) that cannot be removed with surgery or cured with radiation. It aims to see if the combination is safe and effective.
This trial tests a new drug called JSKN016 for people with advanced cancer that has not responded to other treatments. It focuses on certain lung and breast cancers with specific genetic markers.
This trial tests an investigational drug called JSKN033 (given as an injection) for advanced or metastatic non-small cell lung cancer. It aims to see if the drug is safe and effective. Depending on whether you have had prior treatment, you may need a HER2 mutation or HER2 expression in your tumor.
This trial tests a new drug, JSKN022, for people with advanced solid tumors that have stopped responding to standard treatments or are not eligible for them. The goal is to see if the drug is safe and effective.
This trial tests a new drug called JSKN016 given before surgery to shrink tumors in people with stage II or III non-small cell lung cancer. It aims to see if the drug is safe and helps improve outcomes.
This trial tests a new medicine called JSKN016HC for people with advanced solid tumors that have not responded to other treatments. It aims to see if the drug is safe and how it works in the body.
Hear when a new Advanced Non-small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.